share_log

Here's Why We're Not Too Worried About RxSight's (NASDAQ:RXST) Cash Burn Situation

Here's Why We're Not Too Worried About RxSight's (NASDAQ:RXST) Cash Burn Situation

這就是爲什麼我們不太擔心 RxSight(納斯達克股票代碼:RXST)的現金消耗情況
Simply Wall St ·  2023/12/12 05:32

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, RxSight (NASDAQ:RXST) has seen its share price rise 176% over the last year, delighting many shareholders. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

毫無疑問,擁有無利可圖的企業的股份可以賺錢。舉個例子,RxSight(納斯達克股票代碼:RXST)的股價比去年上漲了176%,這讓許多股東感到高興。但是,儘管成功是衆所周知的,但投資者不應忽視許多無利可圖的公司,這些公司只會耗盡所有現金然後倒閉。

Given its strong share price performance, we think it's worthwhile for RxSight shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

鑑於其強勁的股價表現,我們認爲RxSight股東值得考慮其現金消耗是否令人擔憂。就本文而言,我們將現金消耗定義爲公司每年爲其增長提供資金的現金金額(也稱爲負自由現金流)。第一步是將其現金消耗與現金儲備進行比較,爲我們提供 “現金流”。

Check out our latest analysis for RxSight

看看我們對 rxSight 的最新分析

Does RxSight Have A Long Cash Runway?

RxSight 的現金流是否很長?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When RxSight last reported its balance sheet in September 2023, it had zero debt and cash worth US$132m. Importantly, its cash burn was US$51m over the trailing twelve months. So it had a cash runway of about 2.6 years from September 2023. That's decent, giving the company a couple years to develop its business. Depicted below, you can see how its cash holdings have changed over time.

你可以通過將公司的現金金額除以現金的支出率來計算公司的現金流量。當RxSight上次於2023年9月公佈其資產負債表時,其債務爲零,現金價值1.32億美元。重要的是,在過去的十二個月中,其現金消耗爲5100萬美元。因此,從2023年9月起,它的現金流約爲2.6年。這很不錯,這給了公司幾年時間來發展業務。如下所示,您可以看到其現金持有量隨着時間的推移而發生了怎樣的變化。

debt-equity-history-analysis
NasdaqGM:RXST Debt to Equity History December 12th 2023
NasdaqGM: RXST 債券與股本比率歷史記錄 2023 年 12 月 12 日

How Well Is RxSight Growing?

RxSight 的增長情況如何?

On balance, we think it's mildly positive that RxSight trimmed its cash burn by 9.6% over the last twelve months. And arguably the operating revenue growth of 85% was even more impressive. It seems to be growing nicely. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

總的來說,我們認爲RxSight在過去十二個月中將其現金消耗減少了9.6%,這略爲樂觀。可以說,85%的營業收入增長更加令人印象深刻。它似乎增長良好。但是,顯然,關鍵因素是該公司未來是否會發展其業務。因此,你可能想看看該公司在未來幾年預計將增長多少。

Can RxSight Raise More Cash Easily?

RxSight 能否輕鬆籌集更多現金?

There's no doubt RxSight seems to be in a fairly good position, when it comes to managing its cash burn, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

毫無疑問,在管理現金消耗方面,RxSight似乎處於相當有利的地位,但即使這只是假設,也總是值得一問的是,它籌集更多資金爲增長提供資金有多容易。公司可以通過債務或股權籌集資金。上市公司的主要優勢之一是,它們可以向投資者出售股票以籌集現金和爲增長提供資金。我們可以將公司的現金消耗與其市值進行比較,以了解公司必須發行多少新股才能爲一年的運營提供資金。

RxSight's cash burn of US$51m is about 4.0% of its US$1.3b market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

RxSight的5100萬美元現金消耗約爲其13億美元市值的4.0%。這個比例很低,因此我們認爲該公司只要稍加稀釋就能籌集更多現金來爲增長提供資金,甚至可以簡單地借點錢。

How Risky Is RxSight's Cash Burn Situation?

RxSight 的現金消耗情況有多危險?

As you can probably tell by now, we're not too worried about RxSight's cash burn. For example, we think its revenue growth suggests that the company is on a good path. On this analysis its cash burn reduction was its weakest feature, but we are not concerned about it. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Its important for readers to be cognizant of the risks that can affect the company's operations, and we've picked out 2 warning signs for RxSight that investors should know when investing in the stock.

正如你現在可能知道的那樣,我們並不太擔心 RxSight 的現金消耗。例如,我們認爲其收入增長表明公司走上了良好的道路。根據這項分析,其現金消耗減少是其最薄弱的特徵,但我們對此並不擔心。綜合來看本文中的所有衡量標準,我們並不擔心其現金消耗率;該公司的中期支出需求似乎已經完全滿足了。對於讀者來說,了解可能影響公司運營的風險非常重要,我們爲RxSight挑選了兩個警告信號,投資者在投資股票時應該知道這些信號。

Of course RxSight may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

當然,RxSight可能不是最值得購買的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論